Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

Inclusion Criteria Concurrent Medication: Required: * Patients completing ACTG 306 who remain on blinded therapy through the extension period or * Patients on stable (6 months or greater) ddI/3TC or d4T/3TC combination therapy who have plasma HIV-1 levels higher than 500 copies/ml by the Amplicor HIV-1 Monitor Assay. Allowed following contact with Protocol Pharmacologist: * Diltiazem, nifedipine, phenytoin, and warfarin. Patients must have: * Absolute CD4 count of 200 cells/mm3 or greater. * HIV-1 RNA levels greater than 500 copies/ml by the Amplicor HIV-1 Monitor assay. NOTE: * This is a requirement for those receiving study medication. \[AS PER AMENDMENT 12/19/97: * HIV-1 infection must be documented by any licensed ELISA test kit and confirmed by either Western blot, HIV culture, HIV antigen, plasma HIV RNA, or a second antibody test by a method other than ELISA at any time prior to entry.\] * Signed, informed consent from a parent or legal guardian for patients under 18 years of age. * Life expectancy of at least 24 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Unexplained temperature of 38.5 C or higher for 7 consecutive days, or chronic diarrhea defined as more than 3 liquid stools per day persisting for 15 days, within 30 days prior to study entry. * Proven or suspected acute hepatitis within 30 days prior to study entry. * Malignancy that requires systemic chemotherapy. NOTE:Patients with minimal Kaposi's sarcoma (KS) fewer than 5 cutaneous lesions and no visceral disease or tumor-associated edema) are allowed to enroll provided that they do not require systemic therapy. Concurrent Medication: Excluded: * Concurrent ZDV (for patients other than those rolling over from ACTG 306). * Any experimental antiretroviral agents or other experimental therapies. * Acute therapy for an infection or other medical illnesses within 14 days prior to study entry. * Recombinant erythropoietin (rEPO), G-CSF, or GM-CSF within 30 days prior to study entry. * Interferons, interleukins, or HIV vaccines within 30 days prior to study entry. * Rifampin, rifabutin, cisapride, triazolam, midazolam, terfenadine, astemizole, or loratadine, within 14 days prior to study entry. Patients with the following prior conditions are excluded: * History of acute or chronic pancreatitis. * History of Grade 2 or higher bilateral peripheral neuropathy. \[AS PER AMENDMENT 12/19/97: Patients with Grade 2 or 3 peripheral neuropathy due to current use of ddI/3TC or d4T/3TC and who have a screening viral load above 500 copies/ml are eligible as they will be randomized to a regimen that does not contain an agent associated with peripheral neuropathy toxicity.\] Prior Medication: Excluded: * Prior NNRTI or protease inhibitor therapy. * Prior ZDV (for patients other than those rolling over from ACTG 306). * Previous induction or maintenance therapy with foscarnet.